CN105685994A - Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction - Google Patents
Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction Download PDFInfo
- Publication number
- CN105685994A CN105685994A CN201610080090.9A CN201610080090A CN105685994A CN 105685994 A CN105685994 A CN 105685994A CN 201610080090 A CN201610080090 A CN 201610080090A CN 105685994 A CN105685994 A CN 105685994A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- powder
- radix salviae
- salviae miltiorrhizae
- colouring agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 72
- 239000008280 blood Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 150000002632 lipids Chemical class 0.000 title abstract description 17
- 235000013305 food Nutrition 0.000 title abstract description 9
- 230000009467 reduction Effects 0.000 title abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 104
- 235000003935 Hippophae Nutrition 0.000 claims abstract description 49
- 241000229143 Hippophae Species 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 58
- 238000004040 coloring Methods 0.000 claims description 55
- 239000000706 filtrate Substances 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 238000001694 spray drying Methods 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims description 39
- 230000001603 reducing effect Effects 0.000 claims description 38
- 238000010438 heat treatment Methods 0.000 claims description 32
- 235000013402 health food Nutrition 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 27
- 239000002671 adjuvant Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 235000019640 taste Nutrition 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 16
- 238000002791 soaking Methods 0.000 claims description 16
- 229920001353 Dextrin Polymers 0.000 claims description 11
- 239000004375 Dextrin Substances 0.000 claims description 11
- 235000019425 dextrin Nutrition 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 230000036541 health Effects 0.000 abstract description 19
- 239000002994 raw material Substances 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 238000012423 maintenance Methods 0.000 abstract description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 abstract 2
- 241000700159 Rattus Species 0.000 description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 210000002966 serum Anatomy 0.000 description 24
- 239000000284 extract Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 13
- 201000005577 familial hyperlipidemia Diseases 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 108010028554 LDL Cholesterol Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 235000002322 Monascus purpureus Nutrition 0.000 description 8
- 244000113306 Monascus purpureus Species 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 229940057059 monascus purpureus Drugs 0.000 description 8
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 230000006837 decompression Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- -1 flavone compound Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical class C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000000108 ultra-filtration Methods 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 235000019625 fat content Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108700022737 rat Fat1 Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000228347 Monascus <ascomycete fungus> Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229930182482 anthraquinone glycoside Natural products 0.000 description 1
- 229940098421 anthraquinone glycoside Drugs 0.000 description 1
- 150000008139 anthraquinone glycosides Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- MDZKJHQSJHYOHJ-UHFFFAOYSA-N crataegolic acid Natural products C1C(O)C(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MDZKJHQSJHYOHJ-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- MDZKJHQSJHYOHJ-LLICELPBSA-N maslinic acid Chemical compound C1[C@@H](O)[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MDZKJHQSJHYOHJ-LLICELPBSA-N 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Abstract
The invention relates to a healthcare food capable of assisting in blood lipid reduction and a preparation method and application of the healthcare food capable of assisting in blood lipid reduction.The healthcare food capable of assisting in blood lipid reduction comprises, by weight, 6-15 parts of Fermentum Rubrum powder, 15-30 parts of Radix Salviae Miltiorrhizae, 15-30 parts of Fructus Crataegi, 15-30 parts of Fructus Hippophae and 0-30 parts of minor ingredients.Aiming at people high in blood lipid, the healthcare food capable of assisting in blood lipid reduction is prepared according to a formula selecting Fermentum Rubrum, the Radix Salviae Miltiorrhizae, the Fructus Crataegi and the Fructus Hippophae as raw materials by combining modern medical theories on the basis of a traditional Chinese medicine health maintenance theory, and by means of a reasonable ratio, the four raw materials play a role in assistance on blood lipid reduction synergistically, thus, the healthcare food has the healthcare function of assistance on blood lipid reduction.
Description
Technical field
The present invention relates to a kind of health food, its preparation method and application thereof, particularly relate to a kind of health food assisting blood fat reducing and preparation method thereof and application thereof。
Background technology
Along with increasing rapidly of global economy, cardiovascular disease has become as the primary killers threatening human health。The whole world there are about 12,000,000 people every year and dies from cardiovascular diseases and apoplexy, modern medicine thinks that hyperlipemia can cause fatty liver coronary heart disease of hypertension, arteriosclerosis cardiovascular and cerebrovascular disease even dead, so hyperlipemia is referred to as " the stealthy killer " of cardiovascular and cerebrovascular vessel。
Hyperlipemia is owing to lipid metabolism or abnormal one or more lipids made in blood plasma of transhipment are higher than a kind of commonly encountered diseases of normal range, often shows as that serum total cholesterol (TC), triglyceride (TG) or low density lipoprotein, LDL (LDL-C) level are too high and (or) serum High Density Lipoprotein Cholesterol (HDL-C) is too low。Under normal circumstances, the synthesis of human body lipid keeps dynamic equilibrium with decomposing, owing to the factors such as diet (high fat, hypercholesterolemia, Hi CHO food are excessive), disease (obesity, diabetes etc.), hormone then can cause lipid metabolic disorder。The infringement of health is a concealment process increased the weight of slowly, gradually by hyperlipemia。If left, hyperlipidaemic conditions organic growth, is not controlled by, once aggravation, the infringement caused is irreversible often。Reduce blood fat and reduce the maximally effective measure of cardiovascular and cerebrovascular vessel mortality rate beyond doubt。Medical science it turned out, and blood fat reducing can be slowed down the progress of atherosclerotic plaque, significantly reduces cardiovascular and cerebrovascular disease sickness rate, and therefore over nearly 20 years, blood fat reducing is always up the problem that world-wide medical circle is extremely paid attention to。
Hyperlipemia is the appellation of modern medicine, and the traditional Chinese medical science does not have the name of disease of hyperlipemia, but according to its clinical manifestation, can belong to the disease categories such as " expectorant is turbid ", " dizziness ", " blood stasis ", " turbid damp ", " obesity ", " apoplexy ", " cardiopalmus ", " thoracic obstruction "。The formation of hyperlipemia is dirty in close relations with liver,spleen,kidney three, for deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive。The dirty void of liver,spleen,kidney three is this, and expectorant is turbid, blood stasis is mark, belongs to qi-blood-body fluid pathological changes category。Though primary disease pathogenesis is intricate, but outer void, expectorant, the stasis of blood, stagnant four, it is possible to summarize by deficiency and excess。
The current dyslipidemia person of China has 1.6 hundred million people, fatty liver person to have 1.3 hundred million people, and numeral is also in being continuously increased。According to statistics, normal population sickness rate is 20-30%, and in rejuvenation trend year by year。Showing according to an Epidemiological study, the cholesterol that more than 35 years old crowd of China there are about in 23.5% blood exceedes normal level。Dyslipidemia is one of important risk factor causing myocardial infarction and apoplexy, and it is about 3,000,000 that China dies from the number of cardiovascular disease every year, should cause enough attention。2013, the Yang Wenying professor of Ministry of Public Health China-Japan Friendship Hospital, of issue was for the extensive Epidemiological study of Chinese population blood lipid level。Result shows, critical hypercholesterolemia reaches 22.5%, thus calculates, in state-owned more than 200,000,000 critical hypercholesterolemia patients。Therefore actively prevent and treat hyperlipemia tool to be of great significance。
Prevent and treat hyperlipemia, except strengthening self health consciousness, make great efforts to form outside good dietary habit, then add certain intervening measure and seem very necessary。Health food has certain health care, and safety is high, it is possible to eat for a long time, the clinical experience more having traditional medicine long-term is guidance, namely meet the traditional Chinese medical science tradition control principle of " diseases prevention is in possible trouble ", " preventing diseases instead for the treatment of diseases ", the demand of people's daily health caring can be met again。The drug main treating hyperlipemia at present to have clofibrate, nicotinic acid, disappear rouge amine and the big class of lovastatin four, but has certain toxic and side effects, much liver, kidney is had certain infringement, some reduction leukocyte。
Therefore overcoming the drawbacks described above on the medicine treating hyperlipemia at present, a kind of Regulation serum lipids of searching is effective and has no side effect, and the health medicine that simultaneously can treat again cerebral arteriosclerosis, coronary heart disease and fatty liver that hyperlipemia causes is very significant。
Chinese invention patent application file CN101524422A discloses a kind of has the health product of hypolipemic function, their preparation method and purposes。These health product are made up of Hongqu powder (red colouring agent), Fructus Crataegi extract, Folium Ginkgo extract, Semen Cassiae extract and Radix Salviae Miltiorrhizae extract active component, and between component, cooperative effect is obvious, and lipid-lowering effect is notable。It addition, its safety toxicological test proves that safety non-toxic is harmless。The preparation method of Fructus Crataegi extract: weigh Fructus Crataegi powder, extracts 2-4 time according to the weight ratio 1:8 60-80% ethanol water of Fructus Crataegi powder and described alcoholic solution, obtains ethanol extract and merges, filters, and concentration dries and obtains brownish red Fructus Crataegi extract extractum；Described extractum leaches according to the weight ratio 1:3 ethyl acetate of described extractum Yu ethyl acetate at temperature 20-40 DEG C, reduce pressure Distillation recovery ethyl acetate again, the solid obtained is heated reflux, extract, by ethyl acetate again, then decompression Distillation recovery ethyl acetate, residue drying obtains the Fructus Crataegi extract containing total flavones；The preparation of Semen Cassiae extract: weigh Semen Cassiae powder, extract 2-4 time according to the weight ratio 1:8 80-95% ethanol water of Semen Cassiae with described ethanol water, obtain ethanol extract and merge concentration, weight ratio 1:3 chloroform according still further to Semen Cassiae Yu chloroform carries out extracting dissociated anthraquinone, the aqueous solution obtained precipitates with plumbeous compound under pH6-7, isolated by filtration precipitates, and this precipitation of re-dissolved passes into H in the solution obtained2S gas makes the plumbous precipitation wherein contained, and the mother solution and the chloroform solution that obtain after isolated by filtration precipitation concentrate, and vacuum drying obtains the Semen Cassiae extract containing anthraquinone and anthraquinone glycoside；The preparation of Radix Salviae Miltiorrhizae extract: weigh 20-40 order Radix Salviae Miltiorrhizae powder, add 90-95% ethanol water according to the weight ratio 1:10 of Radix Salviae Miltiorrhizae powder Yu described ethanol water to extract, concentration, the concentrate aqueous precipitation obtained 24 hours, it is then centrifuged for separating, the supernatant obtained concentrates, spray drying, pulverizes, sieves, is mixed to get described Radix Salviae Miltiorrhizae extract。But, the preparation process of the Fructus Crataegi extract in these health product having been used ethyl acetate, and ethyl acetate has belonged to hypotoxicity organic reagent, so would be likely to occur residual in Sample Preparation Procedure, the safety of product having been threatened；The preparation process of Semen Cassiae extract is used such as plumbeous compound, chloroformic solution, broadly fall into toxic reagent, if there is residual in the product, will be very huge to healthy hidden danger, it is taken as that the prior art exists bigger potential safety hazard in preparation technology。
Chinese invention patent application file CN102763848A discloses health product and the preparation technology thereof of a kind of blood fat reducing。Wherein these health product comprise raw material Monas cuspurpureus Went, Fructus Crataegi extract and Radix Salviae Miltiorrhizae extract, and adjuvant has microcrystalline Cellulose and magnesium stearate。Its step of preparation process is pre-treatment, sieves, weighs, mixes and capsule filling, polishing, screening。These health product, by improving the function of biological organs, reduce the purpose of blood fat, have curative effect certainly, formula flexibly, few side effects and the advantages such as cardiovascular function can be regulated by Mutiple Targets。But, this health product prescription is made up of Monas cuspurpureus Went, Fructus Crataegi extract and Radix Salviae Miltiorrhizae extract, it is believed that prescription shows slightly simple。
Summary of the invention
The technical problem to be solved is to provide a kind of health food assisting blood fat reducing, has strengthening the spleen and nourishing the stomach, regulates the effective of blood fat, and has no side effect。
For solving above-mentioned technical problem, the present invention provides a kind of health food assisting blood fat reducing, including Hongqu powder (red colouring agent) 6-15 weight portion, Radix Salviae Miltiorrhizae 15-30 weight portion, Fructus Crataegi 15-30 weight portion, Fructus Hippophae 15-30 weight portion, adjuvant 0-30 weight portion。
As a further improvement on the present invention, wherein, described Hongqu powder (red colouring agent) 7-12 weight portion, Radix Salviae Miltiorrhizae 18-28 weight portion, Fructus Crataegi 18-28 weight portion, Fructus Hippophae 18-28 weight portion, adjuvant 18-28 weight portion。
As a further improvement on the present invention, wherein, described Hongqu powder (red colouring agent) 9-12 weight portion, Radix Salviae Miltiorrhizae 20-26 weight portion, Fructus Crataegi 20-26 weight portion, Fructus Hippophae 20-26 weight portion, adjuvant 20-26 weight portion。
As a further improvement on the present invention, wherein, described Hongqu powder (red colouring agent) 11.25 weight portion, Radix Salviae Miltiorrhizae 25 weight portion, Fructus Crataegi 25 weight portion, Fructus Hippophae 25 weight portion, adjuvant 25 weight portion。
As a further improvement on the present invention, wherein, described Hongqu powder (red colouring agent) 9 weight portion, Radix Salviae Miltiorrhizae 23 weight portion, Fructus Crataegi 23 weight portion, Fructus Hippophae 23 weight portion, adjuvant 22 weight portion。
As a further improvement on the present invention, wherein, described Hongqu powder (red colouring agent) 7 weight portion, Radix Salviae Miltiorrhizae 21 weight portion, Fructus Crataegi 21 weight portion, Fructus Hippophae 21 weight portion, adjuvant 30 weight portion。
As a further improvement on the present invention, wherein, described adjuvant at least one in dextrin, maltodextrin, starch, beta-schardinger dextrin-, microcrystalline Cellulose。
The present invention is directed to the crowd of Hyperlipidemia, based on tcm health preserving theory, in conjunction with modern medical theory, screen in strict accordance with the relevant regulations of " health food management method " material choice, selecting Monas cuspurpureus Went, Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae is raw material prescription, has the health care of auxiliary blood fat reducing。In side, Monas cuspurpureus Went is warm in nature, sweet in the mouth, has effect of blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion。Monas cuspurpureus Went is inoculated in the rice fermentation cooked and forms by Monascus fungus, is the wholefood with blood fat reducing, blood pressure lowering and 3 kinds of functions of blood sugar lowering。Modern study finds that it has the effective ingredient such as lovastatin, 7-aminobutyric acid, polyunsaturated fatty acid, flavone compound。Wherein lovastatin class is potent component for reducing blood fat, to the synthesis rate-limiting enzyme (HMC-C of cholesterol in cholesterol in human body building-up process0A reductase) there is efficient Specific Inhibitory Effect, can effectively block the synthesis of internal cholesterol, overall cholesterol levels can be regulated, thus reducing cholesterol in blood plasma, low-density lipoprotein cholesterol and high density lipoprotein increasing cholesterol；Suppress the formation of atheromatous plaque, protect vascular endothelial cell；Lipid is suppressed to deposit at liver。Monas cuspurpureus Went also has the pharmacological actions widely such as resisting fatigue, enhancing immunity simultaneously。In side, Fructus Crataegi has effect of promoting digestion and removing stagnation, blood circulation promoting and blood stasis dispelling, and Compendium of Material Medica calls its " dissipating fluid-retention is eaten, and the meat that disappears amasss, abdominal mass, phlegm retention feeling of fullness acid regurgitation, stagnant blood pain with distension "。Radix Salviae Miltiorrhizae bitter in the mouth, is slightly cold, and enters heart channel, heart governing blood and vessels, and the stasis of blood of the blood vessels that can disappear is stagnant。Radix Salviae Miltiorrhizae Fructus Crataegi is clinical herbal pair, is mainly used in treatment cardiovascular and cerebrovascular disease, and its rules for compatibility is set forth by " Shi Jinmo is to medicine ": Radix Salviae Miltiorrhizae nourshing blood and promoting blood circulation, eliminating blood stasis to promote regeneration of blood；Fructus Crataegi dispelling the stagnated QI blood stasis dispelling, help digestion blood fat reducing；Two medicine 5 use, promoting flow of QI and blood, the power benefit of stasis-dispelling and pain-killing is evident。Modern study shows that Fructus Crataegi is rich in various active materials such as flavone, contributes to expansion blood vessel and increases coronary artery blood flow, contributing to blood fat reducing and blood pressure lowering。Radix Salviae Miltiorrhizae can strengthen myocardial contraction; reduce incidence of arrhythmia and anti peroxidation of lipid; the protective effect of heart is then by coronary artery dilator, increases coronary artery blood flow and oxygen supply, and protects superoxide dismutase (SOD) activity in cardiac muscular tissue to realize。Danshensu can substantially expand the coronary artery of Experimental Acute Myocardial Infarction, increases coronary artery blood flow, contributes to stoping atherosclerotic formation。Containing abundant vitamin, unsaturated fatty acid, flavone compound and multiple bioactive ingredients in Fructus Hippophae。Modern study shows that Fructus Hippophae can effectively regulate blood fat; there is removing people's interior free yl and block peroxidation; the vascular smooth muscle cell of Hyperlipidemic Serum damage there is protective effect; can substantially reduce the content of the lipid peroxide increased in high fat damage smooth muscle cell the activity of the significantly raised SOD of energy。To sum up, these four raw material passes through rational proportion, the collaborative function playing auxiliary blood fat reducing。
The technical problem to be solved is the preparation method also providing for a kind of health food assisting blood fat reducing, it then follows the water extracting method of Chinese Traditional Medicine, easy and simple to handle, and safety is high。
For solving above-mentioned technical problem, the present invention provides a kind of method of health food preparing auxiliary blood fat reducing, comprises the following steps:
A, extraction: take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add water soaking 0.5-2 hour of 8-12 times amount；One decocts heating extraction 0.5-2 hour, filters, and collects filtrate；Two decoct add 5-8 times amount water heating extraction 0.5-2 hour, filter, collect filtrate；
B, concentration: the filtrate obtained in combining step A, be concentrated into 40-60 DEG C when 70-80 DEG C of concentration at, relative density is the extractum of 1.05-1.15；
C, dry: taking the extractum mixing obtained in adjuvant and above-mentioned steps B, at inlet temperature 170-180 DEG C, expect revolution speed 400-500 rev/min, leaving air temp 75-85 DEG C, wind send and carries out spray drying when temperature 30-45 DEG C, obtains spray drying powder；
It is standby that D, Hongqu powder (red colouring agent) cross 100 mesh sieves；
E, preparation: after spray drying powder 100 mesh sieve obtained in above-mentioned steps C, add the Hongqu powder (red colouring agent) mixing obtained in step D；
F, directly or add excipient and make granule, tablet, capsule or oral liquid。
As a further improvement on the present invention, wherein, the method is take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, adds the water soaking 1.5 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate；
Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.10；
Taking adjuvant and the mixing of above-mentioned extractum, inlet temperature 180 DEG C, expect revolution speed 450 revs/min, leaving air temp 85 DEG C, wind send and carries out spray drying when temperature 45 C, obtains spray drying powder；
It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves；
After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, dry method makes granule。
As a further improvement on the present invention, wherein, described spray drying replaces with drying under reduced pressure, microwave drying or lyophilization。
As a further improvement on the present invention, wherein, in technical scheme, Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae extracting mode are carried by water and replace with alcohol extraction。The ethanol extract of this three tastes medicine has the effect of auxiliary blood fat reducing equally。
Detailed description of the invention:
Embodiments of the present invention are specifically described below:
A kind of health food assisting blood fat reducing, including Hongqu powder (red colouring agent) 6-15 weight portion, Radix Salviae Miltiorrhizae 15-30 weight portion, Fructus Crataegi 15-30 weight portion, Fructus Hippophae 15-30 weight portion, adjuvant 15-30 weight portion。Described adjuvant at least one in dextrin, maltodextrin, starch, beta-schardinger dextrin-, microcrystalline Cellulose。
Embodiment 1:
Hongqu powder (red colouring agent) 480g Radix Salviae Miltiorrhizae 840g
Fructus Crataegi 840g Fructus Hippophae 840g
Dextrin 600g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 0.5 hour of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.05；Taking dextrin and the mixing of above-mentioned extractum, inlet temperature 170 DEG C, expect revolution speed 400 revs/min, leaving air temp 75 DEG C, wind send and carries out spray drying when temperature 30 DEG C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, dry method makes granule 1000 bags, every bag of weight 2g。Warm boiled water, twice on the one, one time 1 bag。
Embodiment 2:
Hongqu powder (red colouring agent) 360g Radix Salviae Miltiorrhizae 920g
Fructus Crataegi 920g Fructus Hippophae 920g
Dextrin 880g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 2 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 70 DEG C of concentrations is 1.10；Taking dextrin and the mixing of above-mentioned extractum, inlet temperature 180 DEG C, expect revolution speed 500 revs/min, leaving air temp 85 DEG C, wind send and carries out spray drying when temperature 45 C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, the ethanol with 85% makes granule for adhesive, and reduce pressure oven drying at low temperature, makes capsule 2000, obtains the hard capsule preparation of this health food, every weight 1g。Oral, twice on the one, one time 2。
Embodiment 3:
Hongqu powder (red colouring agent) 280g Radix Salviae Miltiorrhizae 840g
Fructus Crataegi 840g Fructus Hippophae 840g
Microcrystalline Cellulose 1200g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1.5 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 2 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.08；Taking microcrystalline Cellulose and the mixing of above-mentioned extractum, inlet temperature 175 DEG C, expect revolution speed 430 revs/min, leaving air temp 78 DEG C, wind send and carries out spray drying when temperature 42 DEG C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, the ethanol with 80% makes granule for adhesive, and reduce pressure oven drying at low temperature, is pressed into 2000, every tablet weight 1g。Oral, twice on the one, one time 2。
Embodiment 4:
Hongqu powder (red colouring agent) 320g Radix Salviae Miltiorrhizae 860g
Fructus Crataegi 860g Fructus Hippophae 860g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1.5 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate；Merging filtrate, being concentrated at 60 DEG C relative density when 75 DEG C of concentrations is the extractum of 1.20；Above-mentioned extractum adds Hongqu powder (red colouring agent) stir evenly, then the ethanol that mass concentration is 95% is added, alcohol content in the mixed liquor of extractum and ethanol is made to reach 75%, at 10 DEG C, precipitate with ethanol 24 hours, filter, obtaining filtrate, reclaim ethanol, being concentrated into 60 DEG C of relative densities is the extractum of 1.25, filter, obtain extractum filtrate。Above-mentioned extractum filtrate adds volume of dissolution 2 times amount water, stirs evenly, be 2mol/L sodium hydroxide solution by concentration, adjusting pH to 7.2, by carrying out ultrafiltration in the fluid reservoir of hollow-fibre membrane ultrafiltration apparatus, operation pressure is 0.1-0.3Mpa, ultrafiltrate temperature 30-50 DEG C, molecular cut off is 40000-80000, obtains ultrafiltrate, add the potassium sorbate of ultrafiltration volume 0.2%, stir evenly, make 1000 bottles, every bottle of 10mL, oral, twice on the one, each 2 bottles。
Embodiment 5:
Hongqu powder (red colouring agent) 450g Radix Salviae Miltiorrhizae 900g
Fructus Crataegi 850g Fructus Hippophae 800g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1 hour of 10 times amount；One decocts heating extraction 2 hours, filters, and collects filtrate；Two decoct add 8 times amount water heating extraction 1 hour, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 76 DEG C of concentrations is 1.07；60 DEG C of drying under reduced pressure obtain powdered extract powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After drying under reduced pressure powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, the ethanol with 80% makes granule for adhesive, and 60 DEG C of low-temperature reduced-pressures are dried, and are pressed into 2000, every tablet weight 0.5g。Oral, twice on the one, one time 2。
Embodiment 6:
Hongqu powder (red colouring agent) 240g Radix Salviae Miltiorrhizae 1200g
Fructus Crataegi 1200g Fructus Hippophae 1200g
Maltodextrin 700g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1.5 hours of 8 times amount；One decocts heating extraction 2 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.09；Take maltodextrin and the mixing of above-mentioned extractum, 60 DEG C of drying under reduced pressure, obtain drying under reduced pressure powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, dry method makes granule 1000 bags, every bag of weight 2g。Warm boiled water, twice on the one, one time 1 bag。
Embodiment 7:
Hongqu powder (red colouring agent) 300g Radix Salviae Miltiorrhizae 720g
Fructus Crataegi 450g Fructus Hippophae 650g
Beta-schardinger dextrin-450g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1 hour of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.06；Taking powder-beta-dextrin and the mixing of above-mentioned extractum, inlet temperature 176 DEG C, expect revolution speed 420 revs/min, leaving air temp 85 DEG C, wind send and carries out spray drying when temperature 40 DEG C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder 100 mesh sieve, adding Hongqu powder (red colouring agent) mixing, the ethanol with 60% makes granule, 60 DEG C of decompression dryings of low temperature for adhesive, makes capsule 2000, obtains the hard capsule preparation of this health food, every weight 1g。Oral, twice on the one, one time 2。
Embodiment 8:
Hongqu powder (red colouring agent) 400g Radix Salviae Miltiorrhizae 760g
Fructus Crataegi 550g Fructus Hippophae 600g
Starch 450g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1 hour of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1 hour, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 75 DEG C of concentrations is 1.08；Taking powder-beta-dextrin and the mixing of above-mentioned extractum, inlet temperature 185 DEG C, expect revolution speed 400 revs/min, leaving air temp 85 DEG C, wind send and carries out spray drying when temperature 40 DEG C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder 100 mesh sieve, adding Hongqu powder (red colouring agent) mixing, the ethanol with 50% makes granule, 60 DEG C of decompression dryings of low temperature for adhesive, makes capsule 2000, obtains the hard capsule preparation of this health food, every weight 1g。Oral, twice on the one, one time 2。
Embodiment 9:
Hongqu powder (red colouring agent) 350g Radix Salviae Miltiorrhizae 800g
Fructus Crataegi 500g Fructus Hippophae 650g
Maltodextrin 450g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1 hour of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.05；Taking maltodextrin and the mixing of above-mentioned extractum, inlet temperature 182 DEG C, expect revolution speed 410 revs/min, leaving air temp 83 DEG C, wind send and carries out spray drying when temperature 42 DEG C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder 100 mesh sieve, adding Hongqu powder (red colouring agent) mixing, the ethanol with 60% makes granule, 60 DEG C of decompression dryings of low temperature for adhesive, makes capsule 2000, obtains the hard capsule preparation of this health food, every weight 1g。Oral, twice on the one, one time 2。
Embodiment 10:
Hongqu powder (red colouring agent) 340g Radix Salviae Miltiorrhizae 750g
Fructus Crataegi 550g Fructus Hippophae 600g
Beta-schardinger dextrin-400g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1 hour of 10 times amount；One decocts heating extraction 2 hours, filters, and collects filtrate；Two decoct add 8 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 75 DEG C of concentrations is 1.10；Freeze drying process is first extraction concentrated solution to be cooled to-30 DEG C, maintains 3 hours, is then warmed up to-5 DEG C under vacuum, maintains 12 hours, and vacuum is-0.06MPa；Temperature being increased to 30 DEG C further, maintains 6 hours, maintenance vacuum is-0.04MPa, obtains lyophilized powder。Hongqu powder (red colouring agent), lyophilized powder, adjuvant beta-schardinger dextrin-being crossed 100 mesh sieves respectively standby, then by three's mix homogeneously, the ethanol with 40% is that granule made by adhesive, decompression drying at low temperature 60 DEG C, make granule 1000g, obtain the granule of this health food, every bag of weight 1g。Oral, twice on the one, one time 2 bags。
Embodiment 11:
Hongqu powder (red colouring agent) 450g Radix Salviae Miltiorrhizae 1000g
Fructus Crataegi 1000g Fructus Hippophae 1000g
Dextrin 1000g
Take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add the water soaking 1.5 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate。Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.10；Taking dextrin and the mixing of above-mentioned extractum, inlet temperature 180 DEG C, expect revolution speed 400 revs/min, leaving air temp 75 DEG C, wind send and carries out spray drying when temperature 45 C, obtains spray drying powder。It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves。After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, wet method makes granule 1000 bags, every bag of weight 2g。Warm boiled water, twice on the one, one time 1 bag。
In a preferred embodiment of the present invention, this health food also can add the drug excipient of routine, such as solvent, disintegrating agent, correctives, preservative, coloring agent etc., they can select according to different dosage forms, this is easily determined for the technical staff of pharmaceutical technology field, is also apparent from。
Experimental example
Zoopery
1, material and method
1.1 samples: the health product of blood fat reducing of the present invention, content is brownish red granule, and human body recommends consumption to be 4.0g/60kg.bw every day；Blood fat reducing health products of the present invention is not added with the extract powder that adjuvant prepares, and for brown-red powder, human body recommends consumption to be 3.0g/60kg.bw every day。
1.2 laboratory animals: healthy adult male SD rat, body weight 180-200g。Experimental situation 22 DEG C ± 2 DEG C, relative humidity 50% ± 10%。
1.3 model feedstuffs: add 20.0% sucrose, 15% Adeps Sus domestica, 1.2% cholesterol, 0.2% sodium cholate maintaining in feedstuff, appropriate casein, calcium hydrogen phosphate。
1.4 experimental techniques: according to the adnexa 6-auxiliary lipid-lowering function method of inspection of state's food medicine prison guarantorization [2012] 107 that State Food and Drug Administration issues, adopt combined hyperlipidemia familial model to give given the test agent。
1.4.1 the laundering period: rat feeds maintenance feedstuff in zoopery indoor, observe 7 days。
1.4.2 the modeling phase: be randomly divided into 2 groups by body weight, 10 rats give to maintain feedstuff as blank group, and 70 are only given model feedstuff as model control group。Weigh in weekly 1 time。After model control group gives model feedstuff 2 weeks, blank group and model control group rat non-fasting are taken a blood sample (the ophthalmic corner of the eyes or afterbody), separate serum after blood sampling as early as possible, measure serum TC, TG, HDL-C, LDL-C level。
1.4.3 given the test agent gives
(1) granule group
In the present invention, the human body recommended intake of particulate samples is everyone every day of 4000mg, and everyone presses 60kg weighing machine, is equivalent to 67mg/60kg.bw every day。By being equivalent to 5 times of human body recommended amounts, 10 times, the 30 times basic, normal, high dosage determining rat, namely respectively organize rat amount every day respectively 335mg/60kg.bw, 670mg/60kg.bw, 2010mg/60kg.bw。Tested material deionized water is prepared, and gavage gives rat tested material solution once a day, and gavage volume is all by 1ml/100g.bw。Concentration respectively 33.5g/L, 67g/L, 201g/L of basic, normal, high dosage group tested material solution。
(2) pure medicated powder group
In the present invention, the human body recommended intake of pure medicated powder sample is everyone every day of 3000mg, and everyone presses 60kg weighing machine, is equivalent to 50mg/60kg.bw every day。By being equivalent to 5 times of human body recommended amounts, 10 times, the 30 times basic, normal, high dosage determining rat, namely respectively organize rat amount every day respectively 250mg/60kg.bw, 500mg/60kg.bw, 1500mg/60kg.bw。Tested material deionized water is prepared, and gavage gives rat tested material solution once a day, and gavage volume is all by 1ml/100g.bw。Concentration respectively 25g/L, 50g/L, 150g/L of basic, normal, high dosage group tested material solution。
Meanwhile, blank group and model control group gavage give the deionized water of suitable volume。Blank group continues to give to maintain feedstuff, three dosage groups in model control group and particulate samples and medicated powder sample continue to give model feedstuff, give 30 days continuously, regularly weigh in, non-fasting blood sampling when experiment terminates, separate serum after blood sampling as early as possible, measure serum TC, TG, HDL-C, LDL-C level。
1.5 key instruments and reagent: animal balance, electronic balance, low speed centrifuge, 722 type spectrophotometers, thermostat water bath, micro sample adding appliance, operating theater instruments。The test kit measuring TC, TG, HDL-C, LDL-C provides by Zhongsheng Beikong Biological Science & Technology Co., Ltd.。
1.6 experimental data statistics: experiment the data obtained is numerical variable data。All data all carry out variance analysis through SPSS statistical software。
2, experimental result
The impact on rat body weight of 2.1 samples
Modeling model control group is consistent with the rat body weight of blank group, no significant difference。During modeling, after feeding model feedstuff 2 weeks, the rat body weight of model control group and gain in weight are more than blank group, and difference has significance (P < 0.05), in Table 1。During formal test, the gain in weight when rat body weight of model control group weekly and experiment terminate is more than blank group, and difference has significance (P < 0.05)；Experiment was to the 30th day, there are no significant (P > 0.05) for the rat body weight of particulate samples and each dosage group of medicated powder sample and the difference of gain in weight and model control group, in Table 2, it was shown that the body weight growth of the rat that model feedstuff feeds is had no significant effect by particulate samples of the present invention and medicated powder group sample。
Table 1: rat body weight change during modeling
| Group | Number of animals (only) | Initial stage body weight (g) | First week (g) | Second week (g) | Weightening finish (g) |
| Blank group | 10 | 190.3±6.2 | 235.5±14.7 | 275.9±16.3 | 85.6±11.5 |
| Model control group | 70 | 189.4±5.3 | 241.47±9.7 | 289.9±11.6 | 100.5±11.2* |
Table 2: the rat body weight change of each group before and after experiment
Note: * model control group compares with blank group, P < 0.05。Each dosage group compares with model control group, and there are no significant for difference (P > 0.05)。
The impact on rat fat content of 2.2 inventive samples
2.2.1 the front rat fat contents level of experiment is in Table 3, Analysis of variance, before experiment, the Serum TC of model control group, TG, LDL-C content are higher than blank group, difference extremely notable (p < 0.01), it was shown that hyperlipidemia model is set up；Before experiment, the rat blood serum HDL-C content of model control group is basically identical with blank group, and difference does not have significance；Granule group and Serum TC in each dosage group of medicated powder group, TG, HDL-C, LDL-C content are consistent with model control group, no significant difference。
Table 3: respectively organize Serum TC before experiment, TG, HDL C, LDL C content compares
Note: * * model control group compares with blank group, P < 0.01。
2.2.2 after testing, Serum Lipids in Experimental HypercholesterolemicRats is in Table 4: the Serum TC of model control group, TG, LDL-C content are higher than blank group, difference extremely notable (p < 0.01), it was shown that hyperlipidemia model is set up。The no significant difference (p > 0.05) of the rat blood serum HDL-C content of model control group and blank group。
The Serum TC content of each dosage group of granule group and medicated powder group is below model control group, and the difference of high dose group and model control group has significance (p < 0.05), it was shown that inventive samples has the effect of the serum total cholesterol content reducing the rat that model feedstuff feeds。The rat blood serum TG content of granule group and each dosage group of medicated powder group sample is below model control group, and the difference of dosage group high, middle and model control group has significance (p < 0.05), it was shown that inventive samples has the effect of the serum triglycerides content reducing the rat that model feedstuff feeds。The rat blood serum LDL-C content of granule group and each dosage group of medicated powder group sample is lower than model control group, and the difference of each dosage group and model control group all has significance (p < 0.05), it was shown that inventive samples has the serum LDL cholesterol content reducing the rat that model feedstuff feeds without obvious impact。
The rat blood serum HDL-C content of granule group and each dosage group of medicated powder group sample compares with model control group, difference is also without significance (p > 0.05), it was shown that inventive samples on the serum High Density Lipoprotein Cholesterol content of the rat that model feedstuff feeds without obvious impact。
Table 4: respectively organize Serum TC after experiment, TG, HDL C, LDL C content compares
Note: * * model control group compares with blank group, P < 0.01。
3. brief summary
Originally test result indicate that, per os gives the inventive samples of rat various dose, compare with model control group, granule group and each dosage group of medicated powder group sample can reduce the serum total cholesterol (TC) of rat, triglyceride (TG) and serum low-density LP (LDL-C) content, the body weight of rat is increased and serum High Density Lipoprotein Cholesterol (HDL-C) content has no significant effect。According to " health food inspection and assessment technique specification " criterion, granule group of the present invention and medicated powder group sample are respectively provided with auxiliary lipid-lowering function。
The health food preparing above-mentioned auxiliary blood fat reducing is to prepare by the following method, before producing, each supplementary material is tested by company standard, can use, comprise the following steps after each qualified:
A, extraction: take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add water soaking 0.5-2 hour of 8-12 times amount；One decocts heating extraction 0.5-2 hour, filters, and collects filtrate；Two decoct add 5-8 times amount water heating extraction 0.5-2 hour, filter, collect filtrate；
B, concentration: the filtrate obtained in combining step A, be concentrated into 40-60 DEG C when 70-80 DEG C of concentration at, relative density is the extractum of 1.05-1.15；
C, dry: taking the extractum mixing obtained in dextrin and above-mentioned steps B, at inlet temperature 170-180 DEG C, expect revolution speed 400-500 rev/min, leaving air temp 75-85 DEG C, wind send and carries out spray drying when temperature 30-45 DEG C, obtains spray drying powder；
It is standby that D, Hongqu powder (red colouring agent) cross 100 mesh sieves；
E, preparation: after spray drying powder 100 mesh sieve obtained in above-mentioned steps B, add the Hongqu powder (red colouring agent) mixing obtained in step B；
F, directly or add excipient and make granule, tablet, capsule or oral liquid。
The replacement scheme of the present invention: about extraction, in technical scheme, Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae are that water carries, and the ethanol extract of this three tastes medicine has the effect of auxiliary blood fat reducing equally, and therefore its replacement scheme can be alcohol extraction。
About dry, the drying mode mentioned in technical solution of the present invention is spray drying, and its replacement scheme can be drying under reduced pressure, microwave drying or lyophilization。
Advantages of the present invention:
1, in preparation method: the present invention follows the water extracting method of Chinese Traditional Medicine, easy and simple to handle, safety is high。First Fructus Crataegi, Radix Salviae Miltiorrhizae, Fructus Hippophae are carried out aqueous solution and carry altogether, obtain spray drying powder and Hongqu powder (red colouring agent) mixing that condensed water extract obtains, make granule, tablet, capsule etc.。
2, on prescription: the health food with auxiliary blood fat reducing that the present invention makes with Monas cuspurpureus Went, Fructus Crataegi, Radix Salviae Miltiorrhizae, Fructus Hippophae, dextrin for main supplementary material。Monas cuspurpureus Went is warm in nature, sweet in the mouth, has effect of blood circulation promoting and blood stasis dispelling, strengthening the spleen to promote digestion；Crataegolic acid, sweet, tepor。Return spleen, stomach, Liver Channel。There is digestion-promoting spleen-invigorating, circulation of qi promoting dissipating blood stasis, change effect of turbid blood fat reducing；Radix Salviae Miltiorrhizae is bitter, be slightly cold, GUIXIN, Liver Channel。Having blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, clear away heart-fire relieving restlessness, removing heat from blood eliminating carbuncle；Fructus Hippophae contains abundant vitamin, unsaturated fatty acid, flavone compound and multiple bioactive ingredients, there is the pharmacological actions such as the metabolism in blood pressure lowering, blood fat reducing, antioxidation, acceleration human body, heart tonifying, be the medicinal and edible plant assert in the first batch of health ministry。The present invention tends to gentle regulate blood fat, it is intended that while regulating blood fat, do not injure taste and can function of spleen and stomach regulating function, more conform to the Therapeutic Principle of traditional Chinese medical science strengthening the body resistance。So invention is based on invigorating the spleen and benefiting QI, removing damp and turbid, it is aided with blood circulation promoting and blood stasis dispelling, plays effect of blood fat reducing altogether。This four Chinese medicine synergism, lipid-lowering effect is obvious, and the present invention has good strengthening the spleen and nourishing the stomach effect, has no side effect。
The above; being only the present invention preferably detailed description of the invention, but protection scope of the present invention is not limited thereto, any those familiar with the art is in the technical scope that the invention discloses; the change that can readily occur in or replacement, all should be encompassed within protection scope of the present invention。Therefore, protection scope of the present invention should be as the criterion with scope of the claims。
Claims (10)
1. assist a health food for blood fat reducing, including Hongqu powder (red colouring agent) 6-15 weight portion, Radix Salviae Miltiorrhizae 15-30 weight portion, Fructus Crataegi 15-30 weight portion, Fructus Hippophae 15-30 weight portion, adjuvant 0-30 weight portion。
2. a kind of health food assisting blood fat reducing according to claim 1, it is characterised in that: described Hongqu powder (red colouring agent) 7-12 weight portion, Radix Salviae Miltiorrhizae 18-28 weight portion, Fructus Crataegi 18-28 weight portion, Fructus Hippophae 18-28 weight portion, adjuvant 12-28 weight portion。
3. a kind of health food assisting blood fat reducing according to claim 1, it is characterised in that: described Hongqu powder (red colouring agent) 11.25 weight portion, Radix Salviae Miltiorrhizae 25 weight portion, Fructus Crataegi 25 weight portion, Fructus Hippophae 25 weight portion, adjuvant 25 weight portion。
4. a kind of health food assisting blood fat reducing according to claim 1, it is characterised in that: described Hongqu powder (red colouring agent) 9 weight portion, Radix Salviae Miltiorrhizae 23 weight portion, Fructus Crataegi 23 weight portion, Fructus Hippophae 23 weight portion, adjuvant 22 weight portion。
5. a kind of health food assisting blood fat reducing according to claim 1, it is characterised in that: described Hongqu powder (red colouring agent) 7 weight portion, Radix Salviae Miltiorrhizae 21 weight portion, Fructus Crataegi 21 weight portion, Fructus Hippophae 21 weight portion, adjuvant 25 weight portion。
6. a kind of health food assisting blood fat reducing according to any one of claim 1 to 5, it is characterised in that: described adjuvant at least one in dextrin, maltodextrin, starch, beta-schardinger dextrin-, microcrystalline Cellulose。
7. the method preparing the health food assisting blood fat reducing according to any one of claim 1 to 6, comprises the following steps:
A, extraction: take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, add water soaking 0.5-2 hour of 8-12 times amount；One decocts heating extraction 0.5-2 hour, filters, and collects filtrate；Two decoct add 5-8 times amount water heating extraction 0.5-2 hour, filter, collect filtrate；
B, concentration: the filtrate obtained in combining step A, be concentrated into 40-60 DEG C when 70-80 DEG C of concentration at, relative density is the extractum of 1.05-1.15；
C, dry: taking the extractum mixing obtained in adjuvant and above-mentioned steps B, at inlet temperature 170-190 DEG C, expect revolution speed 400-500 rev/min, leaving air temp 75-85 DEG C, wind send and carries out spray drying when temperature 30-45 DEG C, obtains spray drying powder；
It is standby that D, Hongqu powder (red colouring agent) cross 100 mesh sieves；
E, preparation: after the spray drying powder obtained in above-mentioned steps C crosses 100 mesh sieves, add the Hongqu powder (red colouring agent) mixing obtained in step D；
F, directly or add excipient and make granule, tablet, capsule or oral liquid。
8. prepare the method for health food of auxiliary blood fat reducing according to claim 7, it is characterised in that: the method is take the decoction pieces of Radix Salviae Miltiorrhizae, Fructus Crataegi, Fructus Hippophae three taste medicine, adds the water soaking 1.5 hours of 10 times amount；One decocts heating extraction 1.5 hours, filters, and collects filtrate；Two decoct add 6 times amount water heating extraction 1.5 hours, filter, collect filtrate；
Merging filtrate, being concentrated at 60 DEG C relative density when 80 DEG C of concentrations is 1.10；
Taking adjuvant and the mixing of above-mentioned extractum, inlet temperature 180 DEG C, expect revolution speed 450 revs/min, leaving air temp 85 DEG C, wind send and carries out spray drying when temperature 45 C, obtains spray drying powder；
It is standby that Hongqu powder (red colouring agent) crosses 100 mesh sieves；
After spray drying powder crosses 100 mesh sieves, adding Hongqu powder (red colouring agent) mixing, dry or wet makes granule。
9. the method preparing the health food of auxiliary blood fat reducing according to claim 8, it is characterised in that: described spray drying replaces with drying under reduced pressure, microwave drying or lyophilization。
10. the application in the health food of preparation auxiliary adjustment of blood fat of the health food as according to any one of claim 1 to 6。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610080090.9A CN105685994A (en) | 2016-02-04 | 2016-02-04 | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610080090.9A CN105685994A (en) | 2016-02-04 | 2016-02-04 | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105685994A true CN105685994A (en) | 2016-06-22 |
Family
ID=56222235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610080090.9A Pending CN105685994A (en) | 2016-02-04 | 2016-02-04 | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105685994A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168876A (en) * | 2020-09-24 | 2021-01-05 | 江苏康缘药业股份有限公司 | Composition with blood fat reducing effect and preparation method and application thereof |
| CN113892540A (en) * | 2021-10-18 | 2022-01-07 | 中海油能源发展股份有限公司 | Composite soft sweet and preparation method thereof |
| CN114504617A (en) * | 2022-03-11 | 2022-05-17 | 汤臣倍健股份有限公司 | Composition with effect of assisting in reducing blood fat and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593551A (en) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | Blood fat lowering capsule or tablet and its preparation |
| CN101559118A (en) * | 2008-04-14 | 2009-10-21 | 北京卓越同创药物研究院 | Medicine composition with blood fat adjusting effect and preparation method thereof |
| CN101692895A (en) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | Lipid-lowering health food |
| CN102763848A (en) * | 2012-08-10 | 2012-11-07 | 广东太阳神集团有限公司 | Health care product for lowering blood lipid and preparation process thereof |
| CN103169765A (en) * | 2013-03-26 | 2013-06-26 | 汉中永杨医药科技发展有限公司 | Eucommia ulmoides seed oil and red rice compound soft capsule preparation and preparation method thereof |
-
2016
- 2016-02-04 CN CN201610080090.9A patent/CN105685994A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1593551A (en) * | 2004-06-25 | 2005-03-16 | 浙江省医学科学院 | Blood fat lowering capsule or tablet and its preparation |
| CN101559118A (en) * | 2008-04-14 | 2009-10-21 | 北京卓越同创药物研究院 | Medicine composition with blood fat adjusting effect and preparation method thereof |
| CN101692895A (en) * | 2009-10-19 | 2010-04-14 | 闫聿逊 | Lipid-lowering health food |
| CN102763848A (en) * | 2012-08-10 | 2012-11-07 | 广东太阳神集团有限公司 | Health care product for lowering blood lipid and preparation process thereof |
| CN103169765A (en) * | 2013-03-26 | 2013-06-26 | 汉中永杨医药科技发展有限公司 | Eucommia ulmoides seed oil and red rice compound soft capsule preparation and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112168876A (en) * | 2020-09-24 | 2021-01-05 | 江苏康缘药业股份有限公司 | Composition with blood fat reducing effect and preparation method and application thereof |
| WO2022062715A1 (en) * | 2020-09-24 | 2022-03-31 | 江苏康缘药业股份有限公司 | Composition with effect of lowering blood lipids and preparation method therefor and use thereof |
| CN113892540A (en) * | 2021-10-18 | 2022-01-07 | 中海油能源发展股份有限公司 | Composite soft sweet and preparation method thereof |
| CN114504617A (en) * | 2022-03-11 | 2022-05-17 | 汤臣倍健股份有限公司 | Composition with effect of assisting in reducing blood fat and application thereof |
| CN114504617B (en) * | 2022-03-11 | 2023-06-06 | 汤臣倍健股份有限公司 | Composition with auxiliary blood fat reducing effect and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107296949A (en) | Integration of drinking and medicinal herbs compound formulation and its preparation method and application | |
| CN104069464B (en) | For improving spleen and stomach function and improving the herbal cuisine and preparation method of immunoregulation capability | |
| CN104922550A (en) | Traditional Chinese medicine combination and application thereof | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN107952040A (en) | For nursing one's health the Chinese herbal ointment formula and its processing method of obstruction of the circulation of vital energy constitution | |
| CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
| CN106177053A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Pericarpium Citri Reticulatae | |
| CN105685994A (en) | Healthcare food capable of assisting in blood lipid reduction and preparation method and application of healthcare food capable of assisting in blood lipid reduction | |
| CN104286864B (en) | A kind of semen astragali complanati oral liquid improving immunity and preparation method thereof | |
| CN106729214A (en) | Medicine and preparation method thereof for treating gout | |
| CN107125751B (en) | Tortoise powder, preparation method and application thereof | |
| CN103230457B (en) | A kind of Chinese medicine composition treating viral myocarditis and preparation method thereof and purposes | |
| CN105148242A (en) | Medicated diet for conditioning specific endowment constitution and preparation method thereof | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN107198727A (en) | A kind of pharmaceutical composition of beautifying face and moistering lotion promoting blood circulation for regulating menstruation and preparation method thereof | |
| CN103054073B (en) | Beautifying fish scale jelly and preparation method thereof | |
| CN111588029A (en) | Polygonatum sibiricum paste composition | |
| CN111328967A (en) | Method for preparing health porridge for hyperlipidemia patients | |
| CN104587417A (en) | Spleen-invigorating and diuresis-promoting preparation for patients with earlier period cirrhosis and a preparation method | |
| CN105597083B (en) | A kind of pair of liver kidney has health food of auxiliary protection function and preparation method thereof | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN103798475B (en) | Chinese herbal medicine honey tea (sugar-free particles) for improving sub-health status of perimenopause and preparation technology thereof | |
| CN102861223A (en) | Seven-medicament diabetes treating capsule | |
| CN109381631A (en) | Compound consolidates muscles and bones and supports nephrons pulvis | |
| CN114617934B (en) | Detoxifying and whitening soup |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |